Purchase this article with an account.
R. Singh, P. E. Carvounis, J. Heffez, A. Kopel, E. Holz; Treatment of Retinal Pigment Epithelium Detachment Associated With Age-Related Macular Degeneration With Bevacizumab or Combination Photodynamic Therapy/ Intravitreous Triamcinolone Acetonide. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4558.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare intravitreous bevacizumab (AVA) to photodynamic therapy and intravitreous triamcinolone (PDT+IVTK), for the treatment of pigment epithelial detachments (PEDs) associated with age-related macular degeneration (ARMD).
Retrospective comparative study of 21 eyes of 21 consecutive patients with ARMD-associated PEDs, initial visual acuity better than 20/200, treated with one or more sessions of AVA (9 eyes of 9 patients) or PDT+IVTK (12 eyes of 12 patients)
Baseline logMAR visual acuity was similar in the two groups (AVA group: 0.53 (20/67), PDT+IVTK group: 0.48 (20/61), p=0.73). At 6 months, logMAR visual acuity was significantly better in the AVA group compared to the PDT+IVTK group (AVA group: 0.34 (20/44), PDT+IVTK group: 0.70 (20/100), p=0.007). The majority of PEDs persisted (AVA group: 5/9, PDT+IVTK group: 5/12, p=0.41) whereas 3/12 eyes treated with PDT+IVTK developed a RPE tear (compared to none in the AVA group, p=0.22).
Treatment of PEDs associated with ARMD with bevacizumab may result in superior visual outcomes compared to treatment with combination photodynamic therapy/intravitreous triamcinolone acetonide.
This PDF is available to Subscribers Only